GlaxoSmithKline Plc (GSK) faces at least four U.K. lawsuits over its Avandia diabetes drug amid
claims it’s linked to an increased risk of heart attacks and congestive heart
failure.
The potential
number of claims against the U.K.’s biggest drugmaker may increase, said Daniel
Slade, a lawyer at Manchester firm Express
Solicitors, who represents consumers in the four suits and has a
further 15 clients.
“We expect the
number of claims to increase as there are potentially thousands of people out
there who took Avandia in the U.K.,” Slade said in a telephone interview today.
“Hopefully these claims will lead to more careful studies and checks on drugs
that are widely marketed.”
Glaxo has said it
paid more than $3 billion to settle U.S. federal and state government claims
that it illegally marketed Avandia, once the world’s best-selling diabetes
pill, and other medications.
No comments:
Post a Comment